Compare Estee Lauder Companies Inc (EL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Repligen Corporation Common Stock — how do they compare? Estee Lauder Companies Inc trades at $101.99 (market cap $36.13B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Estee Lauder Companies Inc is far larger — about 3.2× Repligen Corporation Common Stock's market cap, and Estee Lauder Companies Inc pays a 1.4% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 123 Days and Repligen Corporation Common Stock for 0 Days on average.
| EL | RGEN | |
|---|---|---|
Market Cap | $36.13B | $11.14B |
Volume | 1,925,948 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $194.57 |
52-Week Low | $67.23 | $102.87 |
Typical Hold Time | 123 Days | 0 Days |
Enterprise Value | $41.88B | $11.02B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $101.59, up 1.55% with strong technical momentum and bullish moving average signals. The company shows improving operational trends with three consecutive quarterly earnings beats, though 2025 results reflect a net loss of $1.13B amid revenue contraction. Recent strategic partnerships in AI marketing and leadership appointments signal transformation efforts, while analyst consensus remains positive with a $103 price target.
The stock presents a turnaround opportunity with margin recovery potential and digital innovation initiatives, but faces execution risks from competitive pressures and debt levels. Current valuation multiples appear elevated relative to profitability metrics, requiring careful monitoring of Q3 2026 earnings delivery for confirmation of sustained improvement.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
